The course of blood concentrations of immunotherapy during and after treatment

Phase 1

• Conditions: multiple cancers; Therapeutic area: Diseases [C] - Cancer [C04]

• Registration Number: EUCTR2021-001509-66-NL
• Lead Sponsor: Radboud University Medical Center

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2021-07-08
• Last Update Posted: 2 August 2021

Recruitment & Eligibility

• Status: Authorised-recruitment may be ongoing or finished
• Sex: All
• Target Recruitment: 140

Inclusion Criteria

- Treatment with the ICIs mentioned in paragraph 4.1
- Willingness and ability to provide written IC
- Age 18 years or older

Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 70
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 70

Exclusion Criteria

Since we aim to assess the real-world pharmacokinetics, we will not make use of any exclusion criteria.

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified